#  @Tim_Corr Tim Tim posts on X about $qure, in the, lack of, $rgnx the most. They currently have [---] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::165600083/interactions)  - [--] Month [------] +11,300% ### Mentions: [--] [#](/creator/twitter::165600083/posts_active)  ### Followers: [---] [#](/creator/twitter::165600083/followers)  - [--] Month [---] +14% ### CreatorRank: undefined [#](/creator/twitter::165600083/influencer_rank)  ### Social Influence **Social topic influence** [$qure](/topic/$qure), [in the](/topic/in-the), [lack of](/topic/lack-of), [$rgnx](/topic/$rgnx), [the new](/topic/the-new), [this is](/topic/this-is), [i want](/topic/i-want), [can you](/topic/can-you), [link](/topic/link), [the world](/topic/the-world) **Top accounts mentioned or mentioned by** [@hawkking1515](/creator/undefined) [@mike98572986](/creator/undefined) [@biotechautist](/creator/undefined) [@unknowntester](/creator/undefined) [@canoebrookbl](/creator/undefined) [@petermantas](/creator/undefined) **Top assets mentioned** [uniQure N.V. (QURE)](/topic/$qure) ### Top Social Posts Top posts by engagements in the last [--] hours "UniQures Nov [--] FDA setback on AMT-130 looks more like a procedural reset than a scientific rejection. FDA said the external control approach was no longer adequate despite no new data. $QURE" [X Link](https://x.com/anyuser/status/1989432856754737201) 2025-11-14T20:38Z [---] followers, [----] engagements "Nine days later Makary + Prasad published the NEJM plausible mechanism pathwaya framework built for monogenic diseases where placebo controls arent feasible and external controls are standard. AMT-130 fits this structure almost exactly. $QURE" [X Link](https://x.com/Tim_Corr/status/1989432858646384925) 2025-11-14T20:38Z [---] followers, [----] engagements "UniQures language (currently no longer agrees timely accelerated approval path forward) and the absence of new safety/efficacy concerns support this. $QURE" [X Link](https://x.com/anyuser/status/1989432862303818213) 2025-11-14T20:38Z [---] followers, [---] engagements "The market read Nov [--] as a failure but the broader sequence points to regulatory repositioning not FDA walking away. $QURE" [X Link](https://x.com/anyuser/status/1989432864849760768) 2025-11-14T20:38Z [---] followers, [---] engagements "@hawkking1515 @mike98572986 $QURE" [X Link](https://x.com/Tim_Corr/status/1989714407941620031) 2025-11-15T15:17Z [---] followers, [---] engagements "@BiotechAutist Great thread. Thanks for your insight and analysis. I believe FDA's decision on this will be the barometer for $QURE and amt-130" [X Link](https://x.com/Tim_Corr/status/2012178117633208320) 2026-01-16T15:00Z [--] followers, [---] engagements "The tell in the Moderna decision wasnt the rejection - it was the lack of a roadmap. FDA gives fixes when it sees a path ( $RGNX $QURE) silence is deliberate doctrine-setting under Makary/Prasad" [X Link](https://x.com/anyuser/status/2021420430012318155) 2026-02-11T03:06Z [---] followers, [---] engagements "This is why FDA engagement with $QURE matters. Type A meetings are about how not whether. Under the new doctrine: clinical outcomes first surrogates as support context over platforms. Silence vs engagement is the signal" [X Link](https://x.com/anyuser/status/2021422013450207424) 2026-02-11T03:12Z [---] followers, [---] engagements "@unknown_tester_ @canoebrookbl Can you share that note where Matt called MM his guy" [X Link](https://x.com/Tim_Corr/status/2022495680011321448) 2026-02-14T02:18Z [---] followers, [---] engagements "Link: https://backofthenapkinbios.substack.com/p/best-ideas-only-update-uniqure-qure https://backofthenapkinbios.substack.com/p/best-ideas-only-update-uniqure-qure" [X Link](https://x.com/anyuser/status/2023106033384640542) 2026-02-15T18:44Z [----] followers, [----] engagements "$QURE One point I believe the market may be underpricing is how robust the CHDI Enroll HD data is" [X Link](https://x.com/anyuser/status/2022710809348964803) 2026-02-14T16:33Z [---] followers, [----] engagements "$QURE ENROLL-HD is the largest longitudinal HD dataset in the world designed specifically to model disease progression and support trial endpoints. Very few rare diseases have this level of scientific depth behind them" [X Link](https://x.com/anyuser/status/2022710812817739925) 2026-02-14T16:33Z [---] followers, [----] engagements "$QURE A robust external control reduces counterfactual uncertainty which strengthens the statistical weight of observed clinical separation" [X Link](https://x.com/anyuser/status/2022712028964495611) 2026-02-14T16:38Z [---] followers, [---] engagements "This is why FDA engagement with $QURE matters. Type A meetings are about how not whether. Under the new doctrine: clinical outcomes first surrogates as support context over platforms. Silence vs engagement is the signal" [X Link](https://x.com/anyuser/status/2021422013450207424) 2026-02-11T03:12Z [---] followers, [---] engagements "The tell in the Moderna decision wasnt the rejection - it was the lack of a roadmap. FDA gives fixes when it sees a path ( $RGNX $QURE) silence is deliberate doctrine-setting under Makary/Prasad" [X Link](https://x.com/anyuser/status/2021420430012318155) 2026-02-11T03:06Z [---] followers, [---] engagements "https://open.substack.com/pub/backofthenapkinbios/p/how-rgnx-got-qured-a-regulatory-regimer=2fri1p&utm_medium=ios https://open.substack.com/pub/backofthenapkinbios/p/how-rgnx-got-qured-a-regulatory-regimer=2fri1p&utm_medium=ios" [X Link](https://x.com/anyuser/status/2021168518167777506) 2026-02-10T10:25Z [---] followers, [---] engagements "RT @peter_mantas: I want to be very clear about this re: $QURE. The only people still debating whether AMT-130 is approvable are investors" [X Link](https://x.com/anyuser/status/2013695034424483971) 2026-01-20T19:28Z [---] followers, [--] engagements "I want to be very clear about this re: $QURE. The only people still debating whether AMT-130 is approvable are investors who dont understand how drugs actually die. The FDA does not convene Type A meetings to explain failure and companies do not discuss filing a BLA at any time unless the agency has already accepted the evidence in principle. Failed programs are told to go back and generate new data; viable ones are told how to format stress-test and confirm the data they already have. When the disagreement collapses into SAP mechanics sensitivity analyses and post-marketing requirements" [X Link](https://x.com/anyuser/status/2013686486957265189) 2026-01-20T18:54Z [----] followers, 25.7K engagements "$QURE Encouraging Takeaways for AMT-130 From Management Meeting How does FDA under Prasad change this opinion from back in May according to GS report posted under $SGMO How could they do a [---] on $QURE AMT130 guidance where they agreed upon a path forward for BLA submission early next year https://t.co/UGiqipMSfx How does FDA under Prasad change this opinion from back in May according to GS report posted under $SGMO How could they do a [---] on $QURE AMT130 guidance where they agreed upon a path forward for BLA submission early next year https://t.co/UGiqipMSfx" [X Link](https://x.com/anyuser/status/2013580271275086119) 2026-01-20T11:52Z [----] followers, 35.8K engagements "UniQures Nov [--] FDA setback on AMT-130 looks more like a procedural reset than a scientific rejection. FDA said the external control approach was no longer adequate despite no new data. $QURE" [X Link](https://x.com/anyuser/status/1989432856754737201) 2025-11-14T20:38Z [---] followers, [----] engagements "UniQures language (currently no longer agrees timely accelerated approval path forward) and the absence of new safety/efficacy concerns support this. $QURE" [X Link](https://x.com/anyuser/status/1989432862303818213) 2025-11-14T20:38Z [---] followers, [---] engagements "The market read Nov [--] as a failure but the broader sequence points to regulatory repositioning not FDA walking away. $QURE" [X Link](https://x.com/anyuser/status/1989432864849760768) 2025-11-14T20:38Z [---] followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@Tim_Corr Tim
Tim posts on X about $qure, in the, lack of, $rgnx the most. They currently have [---] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Month [------] +11,300%
Mentions: [--] #
Followers: [---] #
- [--] Month [---] +14%
CreatorRank: undefined #
Social Influence
Social topic influence $qure, in the, lack of, $rgnx, the new, this is, i want, can you, link, the world
Top accounts mentioned or mentioned by @hawkking1515 @mike98572986 @biotechautist @unknowntester @canoebrookbl @petermantas
Top assets mentioned uniQure N.V. (QURE)
Top Social Posts
Top posts by engagements in the last [--] hours
"UniQures Nov [--] FDA setback on AMT-130 looks more like a procedural reset than a scientific rejection. FDA said the external control approach was no longer adequate despite no new data. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [----] engagements
"Nine days later Makary + Prasad published the NEJM plausible mechanism pathwaya framework built for monogenic diseases where placebo controls arent feasible and external controls are standard. AMT-130 fits this structure almost exactly. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [----] engagements
"UniQures language (currently no longer agrees timely accelerated approval path forward) and the absence of new safety/efficacy concerns support this. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [---] engagements
"The market read Nov [--] as a failure but the broader sequence points to regulatory repositioning not FDA walking away. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [---] engagements
"@hawkking1515 @mike98572986 $QURE"
X Link 2025-11-15T15:17Z [---] followers, [---] engagements
"@BiotechAutist Great thread. Thanks for your insight and analysis. I believe FDA's decision on this will be the barometer for $QURE and amt-130"
X Link 2026-01-16T15:00Z [--] followers, [---] engagements
"The tell in the Moderna decision wasnt the rejection - it was the lack of a roadmap. FDA gives fixes when it sees a path ( $RGNX $QURE) silence is deliberate doctrine-setting under Makary/Prasad"
X Link 2026-02-11T03:06Z [---] followers, [---] engagements
"This is why FDA engagement with $QURE matters. Type A meetings are about how not whether. Under the new doctrine: clinical outcomes first surrogates as support context over platforms. Silence vs engagement is the signal"
X Link 2026-02-11T03:12Z [---] followers, [---] engagements
"@unknown_tester_ @canoebrookbl Can you share that note where Matt called MM his guy"
X Link 2026-02-14T02:18Z [---] followers, [---] engagements
"Link: https://backofthenapkinbios.substack.com/p/best-ideas-only-update-uniqure-qure https://backofthenapkinbios.substack.com/p/best-ideas-only-update-uniqure-qure"
X Link 2026-02-15T18:44Z [----] followers, [----] engagements
"$QURE One point I believe the market may be underpricing is how robust the CHDI Enroll HD data is"
X Link 2026-02-14T16:33Z [---] followers, [----] engagements
"$QURE ENROLL-HD is the largest longitudinal HD dataset in the world designed specifically to model disease progression and support trial endpoints. Very few rare diseases have this level of scientific depth behind them"
X Link 2026-02-14T16:33Z [---] followers, [----] engagements
"$QURE A robust external control reduces counterfactual uncertainty which strengthens the statistical weight of observed clinical separation"
X Link 2026-02-14T16:38Z [---] followers, [---] engagements
"This is why FDA engagement with $QURE matters. Type A meetings are about how not whether. Under the new doctrine: clinical outcomes first surrogates as support context over platforms. Silence vs engagement is the signal"
X Link 2026-02-11T03:12Z [---] followers, [---] engagements
"The tell in the Moderna decision wasnt the rejection - it was the lack of a roadmap. FDA gives fixes when it sees a path ( $RGNX $QURE) silence is deliberate doctrine-setting under Makary/Prasad"
X Link 2026-02-11T03:06Z [---] followers, [---] engagements
"https://open.substack.com/pub/backofthenapkinbios/p/how-rgnx-got-qured-a-regulatory-regimer=2fri1p&utm_medium=ios https://open.substack.com/pub/backofthenapkinbios/p/how-rgnx-got-qured-a-regulatory-regimer=2fri1p&utm_medium=ios"
X Link 2026-02-10T10:25Z [---] followers, [---] engagements
"RT @peter_mantas: I want to be very clear about this re: $QURE. The only people still debating whether AMT-130 is approvable are investors"
X Link 2026-01-20T19:28Z [---] followers, [--] engagements
"I want to be very clear about this re: $QURE. The only people still debating whether AMT-130 is approvable are investors who dont understand how drugs actually die. The FDA does not convene Type A meetings to explain failure and companies do not discuss filing a BLA at any time unless the agency has already accepted the evidence in principle. Failed programs are told to go back and generate new data; viable ones are told how to format stress-test and confirm the data they already have. When the disagreement collapses into SAP mechanics sensitivity analyses and post-marketing requirements"
X Link 2026-01-20T18:54Z [----] followers, 25.7K engagements
"$QURE Encouraging Takeaways for AMT-130 From Management Meeting How does FDA under Prasad change this opinion from back in May according to GS report posted under $SGMO How could they do a [---] on $QURE AMT130 guidance where they agreed upon a path forward for BLA submission early next year https://t.co/UGiqipMSfx How does FDA under Prasad change this opinion from back in May according to GS report posted under $SGMO How could they do a [---] on $QURE AMT130 guidance where they agreed upon a path forward for BLA submission early next year https://t.co/UGiqipMSfx"
X Link 2026-01-20T11:52Z [----] followers, 35.8K engagements
"UniQures Nov [--] FDA setback on AMT-130 looks more like a procedural reset than a scientific rejection. FDA said the external control approach was no longer adequate despite no new data. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [----] engagements
"UniQures language (currently no longer agrees timely accelerated approval path forward) and the absence of new safety/efficacy concerns support this. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [---] engagements
"The market read Nov [--] as a failure but the broader sequence points to regulatory repositioning not FDA walking away. $QURE"
X Link 2025-11-14T20:38Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing